BACKGROUND: Most data on the clinical epidemiology of atrial fibrillation (AF) come from Western populations, and data for Asians are limited. We investigated the lifetime risk and projected number of AF among Asians. The annual risks of adverse events among patients with AF, time trends, and the risks compared with patients without AF were analyzed.
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, and its prevalence is projected to rise continuously over the next few decades because of an aging population. 1 The lifetime risks for development of AF have been quoted as 1 in 4 for men and women 40 years of age and older on the basis of Framingham Heart Study data. 2 In the Rotterdam study, the lifetime risk of developing AF at the age of 55 years was 23.8% in men and 22.2% in women. 3 In contrast to such extensive data in the white population, 4 time trends in the incidence, prevalence, and lifetime risks of AF among Asians are limited.
AF has a large effect on a person's health. Historical studies have shown that AF is associated with an increased risk of ischemic stroke, mortality, and heart failure. [5] [6] [7] AF has been reported as an important risk factor for dementia, myocardial infarction, and sudden cardiac death. [8] [9] [10] [11] Again, most AF clinical epidemiology has been made on the basis of studies mainly enrolling a Caucasian population in America and Europe; the risk of adverse events (AEs) of Asian patients with AF has not been well studied.
We investigated the incidence, prevalence, lifetime risk, and projected number of AF among Asians. Second, we investigated the annual risks of AEs among patients with AF, time trends, and the risks compared with patients without AF.
Methods

Database
This study used the National Health Insurance Research Database (NHIRD) released by the Taiwan National Health Research Institutes. The National Health Insurance system is a mandatory universal health insurance program launched on March 1, 1995 , that offers comprehensive medical care coverage to all Taiwanese residents. NHIRD consists of detailed health care data from > 23 million enrollees, representing > 99% of Taiwan's population between January 1, 1996, and December 31, 2011. In this cohort dataset, the patients' original identification numbers have been encrypted to protect their privacy; the encrypting procedure was consistent so that a linkage of the claims belonging to the same patient was feasible within the National Health Insurance database and can be followed continuously. The details about the Taiwan NHIRD can be found at http://nhird.nhri.org.tw/en/Data_Files.html.
Study Population
From January 1, 2000, through December 31, 2011, a total of 289,559 patients aged $ 20 years experienced new-onset AF. AF was assumed to be new onset if no diagnosis of AF could be traced within the NHIRD from January 1, 1996, to the index date. The detailed health care data of each patient with AF were available to December 31, 2011, unless mortality occurred earlier. AF was diagnosed using the International Classification of Diseases, Ninth Revision, Clinical Modification codes (427.31) registered by the physicians responsible for treating these patients. To ensure the accuracy of diagnosis, we defined patients with AF only when it was a discharge diagnosis or confirmed at least twice in the outpatient department. We defined the date of discharge or the date of the second documented AF in the outpatient department as the index date. The diagnostic accuracy of AF using the NHIRD definition has been validated previously. 12, 13 Among the AF cohort, 158,283 patients (54.7%) had received their diagnosis using the discharge diagnosis. For patients who received a diagnosis in the outpatient department (n ¼ 131,276), the median durations between these two outpatient visits were 16 days (interquartile range, 7-56 days). For each patient with AF, an age-(same age in years) and sex-matched subject without AF was identified from the NHIRD at the same index date; the risk of AEs were compared between patients with and without AF. Patients were defined as patients without AF if no any diagnosis of AF could be traced within the NHIRD.
Incidence, Prevalence, and Projected Number of AF
Crude incidence rates for AF of each year were calculated by dividing the number of incident cases of AF by the number of person-years accumulated by all Taiwanese residents within 1 year.
The person-years of follow-up in each year are shown in Table 1 . The prevalence of AF was calculated by dividing the number of patients with AF alive at the end of each year by the number of Taiwanese residents alive at the end of each year. The incidence and prevalence rates of AF for men and women with a 10-year age strata were analyzed on the basis of the incidence and prevalence rates in year 2011. For the calculation of lifetime risk, the method proposed by Sasieni and Adams 14 was used. The incidence of AF among patients without death for each age attained during the 12-year period was calculated. Lifetime risk estimates reflect the sum of age-specific incidences from study entry to age at last observation.
The formula used to calculate the projected prevalence of AF and its detailed descriptions are similar to the study by Lane et al. 15 The 
projection of the prevalence of AF, p ij , at age level i in year j was calculated iteratively on the basis of age level incidence r i and mortality M i as
with the overall relative mortality of patients with AF, RR AF , assumed to be constant across all ages. An annual constant increase in incidence may be given as q > 0, also implying equal relative increase across age groups. Incidence of AF was made on the basis of the AF incidence rate in Taiwan in 2011 stratified for seven age groups (20-29 [16] [17] [18] We investigated the risk of first-time rather than recurrent events after incident AF and aimed to provide a picture of the disease course, namely the subsequent risks of important AEs after new-onset AF. Because the risks of ischemic stroke and myocardial infarction could be significantly reduced with the use of antithrombotic therapies, we analyzed these risks among patients who did not receive antithrombotic therapies within 90 days after the index date. Incidence rate (per 100 person-years) of AEs was calculated from dividing the number of event by person-time at risk; data are presented as the annual risk (%/year).
The risk of ischemic stroke was analyzed among patients with AF and compared with that of patients without AF and no history of ischemic stroke who did not receive antithrombotic therapies (n ¼ 143,684 in each group). The risk of myocardial infarction was analyzed among those with AF and compared with that of patients without AF and no history of myocardial infarction who did not receive antithrombotic therapies (n ¼ 135,065 in each group). The risk of heart failure, dementia, and sudden cardiac death were analyzed among patients with AF and compared with that of patients without AF and no history of these events, with patient numbers of 166,740, 268,679, and 288,180, respectively, in each group.
Statistical Analysis
Data are presented as the mean value and standard deviation for continuous variables and proportions for categorical variables. The differences between normally distributed continuous values were assessed using an unpaired two-tailed t test or one-way analysis of variance for comparing the three groups. The differences between nominal variables were compared byc 2 test. The AE cumulative incidence curves were plotted using the Aalen-Johansen estimator, with mortality being the competing risk. The risk of AEs for patients with and without AF were compared using Cox regression analyses adjusted for age, sex, and comorbidities, including hypertension, diabetes mellitus, heart failure, vascular diseases, and previous history ischemic stroke/transient ischemic attack. We also investigated the HRs of mortality, heart failure, and ischemic stroke of AF compared with patients without AF in different periods ("1-month interval within 2 years" and "> 2 years") after the index date. Data were analyzed using ySPSS PASW statistical software (IBM Corporation), and all statistical significances were set at a P < .05.
The present study was approved by the institutional review board at Taipei Veterans General Hospital (2016-03-002AC and 2017-07-003BC), Taipei, Taiwan; informed consent of study subjects was waived.
Results
The mean age of the 289,559 patients with AF was 71.5 AE 13.3 years; 55.3% were men. Mean congestive heart failure, hypertension, age > 75 years, diabetes mellitus, and prior stroke (CHADS 2 ) and congestive heart failure, hypertension, diabetes mellitus, stroke, vascular disease, age, and sex category (CHA 2 DS 2 -VASc) scores of the overall AF cohort were 2.69 and 4.14, respectively; hypertension was the most prevalent comorbidity, noted in 74.1% of patients. Table 2 presents the baseline characteristics of the AF cohort overall and by time period . Also, the prevalences of important comorbidities at the time of AF diagnosis increased. Owing to the increase in age and comorbidities, the CHADS 2 and CHA 2 DS 2 -VASc scores of incident patients with AF who received a diagnosis in each year showed a trend to become higher with successive year (Fig 1) . Figure 2A shows the incidence rate of AF between 2000 and 2011. The incidence of AF in 2011 was 1.51 per 1,000 person-years (Fig 2A) , with a stepwise increase with age ( Fig 2B) . The prevalence rate of AF increased from 0.46% to 1.07% over the 12 years, with a 2.33-fold increase ( Fig 3A) . Compared with subjects aged 50 to 59 years, subjects aged 60 to 69 years had a 2.8-fold higher in AF (2.5% vs 0.9%), whereas subjected aged 70 to 79 years had a nearly 6-fold higher in AF (5.1% vs 0.9%) (Fig 3B) . The projected prevalence rate was estimated to be 4.01% by the year 2050, and the projected number of patients with AF was estimated to be 730,431 in Taiwan (Fig 4) .
The short-term, intermediate-term, and lifetime risks of AF for subjects at different ages are shown in Table 3 . For Chinese adults aged $ 20 years, the lifetime risk of AF was 1 in 7, being higher for men (1 in 6) compared with women (1 in 7) ( Table 3) .
Risk of AEs Among Patients With AF and the Time Trends
Cumulative incidence curves of AEs for patients with AF are shown in Figure 5 , whereas the annual risks of various AEs after AF was diagnosed is shown in Figure 6 . The annual risks were 9.17% for mortality, 8.53% for heart failure, 3.40% for ischemic stroke, chestjournal.org 2.22% for dementia, 1.05% for sudden cardiac death, and 0.51% for myocardial infarction.
The baseline characteristics of patients with or without AF are shown in Fig 6) . Figure 7 shows the HRs of mortality, heart failure, and ischemic stroke of patients with AF compared with patients without AF for different periods after AF was diagnosed. The risk of events of patients with AF was especially higher than patients without AF within the initial period (6 months) after AF was diagnosed (HR, 13.28; 95% CI, 10.89-16.20 within 6 months vs HR, 3.31; 95% CI, 3.23-3.39 after 6 months; P < .001 for ischemic stroke; HR, 5.86; 95% CI, 5.25-6.55 within 6 months vs HR, 3.05; 95% CI, 3.00-3.09 after 6 months; P < .001 for heart failure). The 1-year risk of AEs after incident AF in each year remained broadly similar (Fig 8) .
Discussion
Our principal findings in this large nationwide cohort study of a Chinese population are as follows: (1) the incidence of AF was 1.51 per 1,000 person-years in year 2011, with a lifetime risk of AF being appropriately 1 in 6 for men and 1 in 7 for women aged $ 20 years; (2) the prevalence of AF was 1.07% in 2011 and is estimated to be 4.01% in 2050; and (3) compared with patients without AF, AF was associated with an increased risk of mortality, heart failure, ischemic stroke, dementia, sudden cardiac death, and myocardial infarction.
Incidence, Prevalence, Lifetime Risk and Projection Number of AF
As far as we are aware, this is the largest and most comprehensive insight into the incidence, prevalence, lifetime risk, and projected number of AF among Asians. In a recent review of the AF epidemiology in Asia, the incidence rate of AF was around 5.38 per 1,000 personyears, made on the basis of data from 10 studies that included 8,190 incident patients with AF. 19 Most of the studies included in this systemic review enrolled specific populations, such as those with hyperuricemia, hyperlipidemia, osteoporosis, underweight, heavy alcohol consumption, and the elderly; therefore, the incidence rate of AF may be overestimated and could not be generalized to general Asian population.
Most prior data on AF incidence rates came from studies performed in Europe and North America. For example, the Rotterdam study enrolled subjects aged 55 years and older, where the AF incidence rate was around 9.9/1,000 personyears. 3 Another report from Netherlands studied subjects aged 28 to 75 years, where the incidence rate of AF was 3.3/ 1,000 person-years. 20 The reported incidence rate of AF ranged between 3.3 and 19.2 per 1,000 person-years among predominantly United States-based cohort studies. 3, [21] [22] [23] [24] In the present study, AF incidence in a Chinese population was around 1.51 per 1,000 person-years, which is lower than that of Caucasians. Also, the lifetime risk that was estimated on the basis of AF incidence in Chinese (1 in 6 for men and 1 in 7 for women) in the present study was lower than that reported from Western countries (eg, 1 in 4 in the Framingham Heart Study). chestjournal.org The prevalence rate of AF in our Chinese cohort was around 1.07% in year 2011, which substantially increased with age. Similar to the growing burden of AF all over the world, 25 the AF prevalence and the absolute number of patients with AF will continuously increase in the coming decades in Taiwan according to projected estimations. We have shown a clear trend demonstrating that incident patients with AF were not only becoming older but having more comorbidities. It may suggest that, although an aging population and longer life expectancy are important reasons for the increase in AF prevalence, the concurrent increase in hypertension, heart failure, and other systemic diseases that are also more prevalent in the elderly may also contribute.
In previous community studies, the AF prevalence rate ranged from 0.7% to 1.6% in Asia (0.7% in Korea, 26 1.5% in Singapore, 27 and 1.6% in Japan 28 ). Similar to the incidence rate, the prevalence rate of AF in Asians was generally lower compared with the reported AF prevalence rates in Caucasians (eg, 5.5% in the Rotterdam study). 3, 25 Although the precise mechanisms behind the differences of AF epidemiology between Asians and Caucasians remain unclear, part of this global variation may be attributable to better surveillance in developed countries and that the prevalence of AF in some Asian countries is probably underestimated. 25, 29 The longer life expectancy and more prevalent cardiovascular risk factors and diseases, including smoking, obesity, hypertension, ischemic heart diseases, and diabetes, in developed Western countries may also play important roles. 29 Furthermore, variants at several genetic loci are associated with the development of AF and seem to differ in frequency between populations, and are likely to explain some of the ethnic variation observed in the prevalence of AF.
29-31
Risk of AEs of Asian Patients With AF
AF is associated with an increased risk of several AEs other than ischemic stroke. In a recent meta-analyses that included 104 cohort studies involving 587,867 patients with AF, AF was associated with an increased risk of allcause mortality (relative risk [RR], 1.46), ischemic stroke (RR, 2.33), ischemic heart disease (RR, 1.61), sudden cardiac death (RR, 1.88), heart failure (RR, 4.99), chronic kidney disease (RR, 1.64), and peripheral arterial disease (RR, 1.31). 32 Again, most of the studies included in this meta-analysis mainly enrolled Caucasians, and data about the risk of AEs associated with AF in Asians are limited.
Compared with data mainly from non-Asians, 32 the relative risks associated with AF in Asians were We demonstrated that the risks of ischemic stroke, heart failure, and mortality were especially higher compared with patients without AF within the initial period (approximately 6 months) after AF was first diagnosed. During this vulnerable period, comprehensive evaluation and proactive management of associated comorbidities should be performed.
Although the risk of ischemic stroke associated with AF compared with patients without AF is higher than other events in our cohort with (aHR, 3.34), the annual risks of mortality (9.17%/year) and heart failure (8.53/year) were higher than that of ischemic stroke (3.40%/year). In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial, the majority of deaths is not related to stroke among the anticoagulated AF population. 33 In a recent study from the Loire Valley AF project, cardiovascular deaths accounted for 54% and noncardiovascular for 43% of deaths in patients with AF. 34 The three main causes of death were heart failure (29%), infection (18%), and cancer (12%); only 7% died from stroke. Thus, optimization of management of any underlying heart disease and associated comorbidities should be part of the holistic management approach to improve patient care in AF.
Time Trends of Risk Scores and Risks of AEs
In the present study, we demonstrated that the risk of AEs of patients with AF remained similar and did not decrease over the study period despite improvements in our understanding and management of AF. Nonetheless, only around 15% of patients with AF received appropriate treatments of stroke prevention according to the guideline recommendations in Taiwan. 35 Also, > 50% of patients with AF did not receive rate control treatment, which was associated with a lower risk of mortality. 36 We also found that the baseline stroke scores of patients who recently received a diagnosis of AF were increasingly higher with each subsequent year, which may reflect greater longevity and improved detection of risk factors. Figure 7 -Risk of mortality, heart failure, and ischemic stroke of patients with AF compared with patients without AF in different periods. The event risk of patients with AF was especially higher than in patients without AF within the initial period after AF was diagnosed. The risks of different adverse events were investigated among different subpopulations, as discussed in the Methods section. See Figure 1 legend for expansion of abbreviation.
Study Limitations
There are several limitations in the present study, given the nature of the nationwide registry dataset we used. First, the subtypes of AF (paroxysmal or nonparoxysmal) were not available. Second, the diagnoses of AF and AEs were made on the basis of the International Classification of Diseases-9-CM codes registered by physicians responsible for the care of the patients. No direct evaluations for events were performed. Although the diagnostic accuracies of AF, heart failure, myocardial infarction, and ischemic stroke in Taiwan NHIRD have been validated, 12, 13, [16] [17] [18] the diagnostic accuracies of these diseases in an insurance database may not be as accurate as that of electronic medical records. Third, we investigated the risk of ischemic stroke and myocardial infarction among patients who did not receive antithrombotic therapies within 90 days after incident AF. Because patients may receive antithrombotic therapies during follow-up, the true risk of ischemic stroke and myocardial infarction without treatment of patients with AF may be higher than we reported here. Fourth, the lifetime risk and prevalence projection of AF were estimated using data collected between 2000 and 2011 without considering effects of birth cohort, changes in population demographics, and other comorbidities associated with AF occurrence. Also, the projected prevalence rates and patient numbers of AF were estimated on the basis of and sensitive to several assumptions of the model, such as RR AF ¼ 2.61 and q ¼ 0. Fifth, although we have shown a higher AF prevalence rate among older patients, we were not able to clearly analyze how much of this increase is due to concurrent increases in hypertension, heart failure, or other comorbidities in the elderly. Last, the present study only enrolled Chinese patients; whether the results can be extrapolated to other populations remains uncertain.
Conclusions
The burden of AF among Asian patients is increasing, with a lifetime risk of AF being appropriately 1 in 7. This results in a significant mortality, heart failure, ischemic stroke, dementia, sudden cardiac death, and myocardial infarction. Optimized management of any associated comorbidities should be part of the holistic management approach for AF.
